<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166365">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00932035</url>
  </required_header>
  <id_info>
    <org_study_id>11130</org_study_id>
    <nct_id>NCT00932035</nct_id>
  </id_info>
  <brief_title>Axillary Lymph Node Preservation Surgery in Reducing Lymphedema in Patients With Breast Cancer</brief_title>
  <official_title>Reducing Extremity Lymphedema Through Axillary Lymphatic Preservation Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot phase I and randomized phase II trial studies the best way to perform axillary
      lymph node preservation surgery and to see how well it works in preventing lymphedema in
      patients with breast cancer. Lymph node mapping may help in planning surgery to remove
      breast cancer and affected lymph nodes. It is not yet known whether reverse mapping guided
      axillary lymph node dissection is more effective than standard axillary lymph node
      dissection in preventing lymphedema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES: I. To produce a map of the lymphatic drainage of the upper extremity as
      it relates to breast drainage, to determine the proportion of women undergoing axillary
      lymphadenectomy at risk for lymphedema. II. To determine if blue lymphatics contain lymph
      node metastases. III. To evaluate the incidence of lymphedema and associated other surgical
      related quality of life in those undergoing this procedure as compared to the current
      standard of care.

      OUTLINE: This is a phase I study followed by a randomized phase II study.

      PILOT PORTION: Patients receive isosulfan blue dye subcutaneously (SC) and then undergo
      reverse mapping-guided axillary lymph node dissection.

      RANDOMIZED PORTION: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients
      receive isosulfan blue dye subcutaneously (SC) and then undergo reverse mapping-guided
      axillary lymph node dissection. ARM II: Patients undergo standard axillary lymph node
      dissection and then receive isosulfan blue dye SC.

      After completion of study treatment, patients are followed up periodically.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with arm lymphatics above, at, or below the axillary vein (Pilot)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>A Fisher's exact test with a one-sided alpha of 0.05 will be used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients with positive axillary reverse mapping (ARM) identified nodes</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>A Fisher's exact test with a one-sided alpha of 0.05 will be used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of lymphedema</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Differences between groups for lymphedema will be evaluated using chi-squared tests.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Surgical related quality of life measured using Short Form (SF)-8 Quality of Life Survey Instrument</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>A Fisher's exact test with a one-sided alpha of 0.05 will be used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor status of blue lymph nodes as tumor bearing or non-tumor bearing (Pilot)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Patient and tumor characteristics that correlate with successful mappings will be performed using univariate correlation and logistic regression for multivariate analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictors of lymphedema, including patient age, body mass index, tumor characteristics, and location of arm lymphatics</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Chi-squared testing and student t-tests will be utilized to evaluate the differences in demographics and tumor characteristics between groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (reverse mapping guided axillary lymph node dissection)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive isosulfan blue dye SC and then undergo reverse mapping-guided axillary lymph node dissection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (control)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo standard axillary lymph node dissection and then receive isosulfan blue dye SC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>axillary lymph node dissection</intervention_name>
    <description>Undergo reverse mapping-guided axillary lymph node dissection</description>
    <arm_group_label>Arm I (reverse mapping guided axillary lymph node dissection)</arm_group_label>
    <other_name>isosulfan blue dye</other_name>
    <other_name>Lymphazurin blue dye</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isosulfan blue based lymphatic mapping</intervention_name>
    <arm_group_label>Arm I (reverse mapping guided axillary lymph node dissection)</arm_group_label>
    <arm_group_label>Arm II (control)</arm_group_label>
    <other_name>isosulfan blue dye</other_name>
    <other_name>Lymphazurin blue dye</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>axillary lymph node dissection</intervention_name>
    <description>Undergo standard axillary lymph node dissection</description>
    <arm_group_label>Arm II (control)</arm_group_label>
    <other_name>isosulfan blue dye</other_name>
    <other_name>Lymphazurin blue dye</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (reverse mapping guided axillary lymph node dissection)</arm_group_label>
    <arm_group_label>Arm II (control)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (reverse mapping guided axillary lymph node dissection)</arm_group_label>
    <arm_group_label>Arm II (control)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Patients diagnosed with breast cancer with a planned axillary lymph node dissection
        planned for breast cancer

        Exclusion Criteria:

          -  Prior lymphedema in either arm

          -  Prior history of axillary surgery (except for sentinel node biopsies)

          -  Prior history of chest/axillary radiation

          -  Need for bilateral axillary node dissection surgery

          -  Prior neurologic deficits (either motor or sensory) in ipsilateral arm

          -  Known allergy to vital blue dyes

          -  No prior diagnosis of inflammatory breast cancer

          -  Cannot be pregnant or planning to continue breast-feeding immediately after surgery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-1350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>June 29, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>axillary mapping</keyword>
  <keyword>lymphedema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
